154 related articles for article (PubMed ID: 3115911)
1. Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine.
Griffin CA; Slavik M; Chien SC; Hermann J; Thompson G; Blanc O; Luk GD; Baylin SB; Abeloff MD
Invest New Drugs; 1987; 5(2):177-86. PubMed ID: 3115911
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.
Abeloff MD; Slavik M; Luk GD; Griffin CA; Hermann J; Blanc O; Sjoerdsma A; Baylin SB
J Clin Oncol; 1984 Feb; 2(2):124-30. PubMed ID: 6422008
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.
Love RR; Carbone PP; Verma AK; Gilmore D; Carey P; Tutsch KD; Pomplun M; Wilding G
J Natl Cancer Inst; 1993 May; 85(9):732-7. PubMed ID: 8478959
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma.
Ajani JA; Ota DM; Grossie VB; Abbruzzese JL; Faintuch JS; Patt YZ; Jackson DE; Levin B; Nishioka K
Cancer Chemother Pharmacol; 1990; 26(3):223-6. PubMed ID: 2113439
[TBL] [Abstract][Full Text] [Related]
5. Urinary and erythrocyte polyamines during the evaluation of oral alpha-difluoromethylornithine in a phase I chemoprevention clinical trial.
Pendyala L; Creaven PJ; Porter CW
Cancer Epidemiol Biomarkers Prev; 1993; 2(3):235-41. PubMed ID: 8318876
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of alpha-difluoromethylornithine and methyl-GAG.
Splinter TA; Romijn JC
Eur J Cancer Clin Oncol; 1986 Jan; 22(1):61-7. PubMed ID: 3082642
[TBL] [Abstract][Full Text] [Related]
7. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia.
Mitchell MF; Tortolero-Luna G; Lee JJ; Hittelman WN; Lotan R; Wharton JT; Hong WK; Nishioka K
Clin Cancer Res; 1998 Feb; 4(2):303-10. PubMed ID: 9516915
[TBL] [Abstract][Full Text] [Related]
9. Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels.
Ajani JA; Ota DM; Grossie VB; Levin B; Nishioka K
Cancer Res; 1989 Oct; 49(20):5761-5. PubMed ID: 2507135
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine.
Grossie VB; Ota DM; Ajani JA; Nishioka K
Invest New Drugs; 1991 Nov; 9(4):321-6. PubMed ID: 1804805
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma.
Meyskens FL; Kingsley EM; Glattke T; Loescher L; Booth A
Invest New Drugs; 1986; 4(3):257-62. PubMed ID: 3102397
[TBL] [Abstract][Full Text] [Related]
12. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of intravenous difluoromethylornithine--a polyamine inhibitor.
Maddox AM; Keating MJ; McCredie KE; Estey E; Freireich EJ
Invest New Drugs; 1985; 3(3):287-92. PubMed ID: 3934106
[TBL] [Abstract][Full Text] [Related]
14. Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer.
Abeloff MD; Rosen ST; Luk GD; Baylin SB; Zeltzman M; Sjoerdsma A
Cancer Treat Rep; 1986 Jul; 70(7):843-5. PubMed ID: 3013400
[TBL] [Abstract][Full Text] [Related]
15. Reduction of difluoromethylornithine-induced thrombocytopenia in rats with ornithine while maintaining antitumor activity.
Grossie VB; Ota DM; Ajani JA; Chang TH; Patenia D; Nishioka K
Cancer Res; 1989 Aug; 49(15):4159-62. PubMed ID: 2501023
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of combined alpha interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy.
Ganju V; Edmonson JH; Buckner JC
Invest New Drugs; 1994; 12(1):25-7. PubMed ID: 7960601
[TBL] [Abstract][Full Text] [Related]
17. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
[TBL] [Abstract][Full Text] [Related]
18. Phase I-II clinical trial with alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.
Horn Y; Schechter PJ; Marton LJ
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1103-7. PubMed ID: 3115786
[TBL] [Abstract][Full Text] [Related]
19. Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia.
Chin K; Merali S; Sarić M; Clarkson AB
Antimicrob Agents Chemother; 1996 Oct; 40(10):2318-20. PubMed ID: 8891137
[TBL] [Abstract][Full Text] [Related]
20. Sequential inhibition of polyamine synthesis. A phase I trial of DFMO (alpha-difluoromethylornithine) and methyl-GAG [methylglyoxal-bis(guanylhydrazone)].
Warrell RP; Coonley CJ; Burchenal JH
Cancer Chemother Pharmacol; 1983; 11(2):134-6. PubMed ID: 6414731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
